Click for best price
Postpemic Era Injectable Anthelmintic Drugs Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Injectable Anthelmintic Drugs Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Injectable Anthelmintic Drugs industry at home and abroad, estimate the overall market scale of the Injectable Anthelmintic Drugs industry and the market share of major countries, Injectable Anthelmintic Drugs industry, and study and judge the downstream market demand of Injectable Anthelmintic Drugs through systematic research, Analyze the competition pattern of Injectable Anthelmintic Drugs, so as to help solve the pain points of various stakeholders in Injectable Anthelmintic Drugs industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Injectable Anthelmintic Drugs Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Injectable Anthelmintic Drugs Market?
Novartis
Cipla
Sun Pharmaceutical Industries
Amneal Pharmaceuticals
Zoetis
GlaxoSmithKline
Bayer
Merck
Boehringer Ingelheim International
Major Type of Injectable Anthelmintic Drugs Covered in XYZResearch report:
Benzimidazoles
Piperazine
Imidazothiazole
Spiroindoles
Others
Application Segments Covered in XYZResearch Market
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Veterinary Pharmacies
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Injectable Anthelmintic Drugs Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
81 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Injectable Anthelmintic Drugs Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Injectable Anthelmintic Drugs Market by Value
2.2.1 Global Injectable Anthelmintic Drugs Revenue by Type
2.2.2 Global Injectable Anthelmintic Drugs Market by Value
2.3 Global Injectable Anthelmintic Drugs Market by Sales
2.3.1 Global Injectable Anthelmintic Drugs Sales by Type
2.3.2 Global Injectable Anthelmintic Drugs Market by Sales
3. The Major Driver of Injectable Anthelmintic Drugs Industry
3.1 Historical & Forecast Global Injectable Anthelmintic Drugs Sales and Revenue (2018-2028)
3.2 Largest Application for Injectable Anthelmintic Drugs (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Injectable Anthelmintic Drugs Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Injectable Anthelmintic Drugs Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Injectable Anthelmintic Drugs Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Injectable Anthelmintic Drugs Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Injectable Anthelmintic Drugs Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Injectable Anthelmintic Drugs Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Injectable Anthelmintic Drugs Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Injectable Anthelmintic Drugs Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Injectable Anthelmintic Drugs Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Injectable Anthelmintic Drugs Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Injectable Anthelmintic Drugs Average Price Trend
13.1 Market Price for Each Type of Injectable Anthelmintic Drugs in US (2018-2022)
13.2 Market Price for Each Type of Injectable Anthelmintic Drugs in Europe (2018-2022)
13.3 Market Price for Each Type of Injectable Anthelmintic Drugs in China (2018-2022)
13.4 Market Price for Each Type of Injectable Anthelmintic Drugs in Japan (2018-2022)
13.5 Market Price for Each Type of Injectable Anthelmintic Drugs in India (2018-2022)
13.6 Market Price for Each Type of Injectable Anthelmintic Drugs in Korea (2018-2022)
13.7 Market Price for Each Type of Injectable Anthelmintic Drugs in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Injectable Anthelmintic Drugs in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Injectable Anthelmintic Drugs Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Injectable Anthelmintic Drugs
15. Injectable Anthelmintic Drugs Competitive Landscape
15.1 Novartis
15.1.1 Novartis Company Profiles
15.1.2 Novartis Product Introduction
15.1.3 Novartis Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Cipla
15.2.1 Cipla Company Profiles
15.2.2 Cipla Product Introduction
15.2.3 Cipla Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Sun Pharmaceutical Industries
15.3.1 Sun Pharmaceutical Industries Company Profiles
15.3.2 Sun Pharmaceutical Industries Product Introduction
15.3.3 Sun Pharmaceutical Industries Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Amneal Pharmaceuticals
15.4.1 Amneal Pharmaceuticals Company Profiles
15.4.2 Amneal Pharmaceuticals Product Introduction
15.4.3 Amneal Pharmaceuticals Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Zoetis
15.5.1 Zoetis Company Profiles
15.5.2 Zoetis Product Introduction
15.5.3 Zoetis Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 GlaxoSmithKline
15.6.1 GlaxoSmithKline Company Profiles
15.6.2 GlaxoSmithKline Product Introduction
15.6.3 GlaxoSmithKline Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Bayer
15.7.1 Bayer Company Profiles
15.7.2 Bayer Product Introduction
15.7.3 Bayer Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Merck
15.8.1 Merck Company Profiles
15.8.2 Merck Product Introduction
15.8.3 Merck Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Boehringer Ingelheim International
15.9.1 Boehringer Ingelheim International Company Profiles
15.9.2 Boehringer Ingelheim International Product Introduction
15.9.3 Boehringer Ingelheim International Injectable Anthelmintic Drugs Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Injectable Anthelmintic Drugs Industry (Volume)
Figure 2. Injectable Anthelmintic Drugs Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Injectable Anthelmintic Drugs Revenue in 2022
Figure 5. US Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Injectable Anthelmintic Drugs Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Injectable Anthelmintic Drugs Revenue, by Type (Million USD) (2018-2028)
Table 4. Injectable Anthelmintic Drugs Sales, by Type (K Unit) (2018-2028)
Table 5. Injectable Anthelmintic Drugs Sales (K Unit) by Application (2018-2028)
Table 6. Injectable Anthelmintic Drugs Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Injectable Anthelmintic Drugs Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Injectable Anthelmintic Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Injectable Anthelmintic Drugs in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Novartis Profiles
Table 61. Novartis Injectable Anthelmintic Drugs Product Introduction
Table 62. Novartis Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Novartis Strategic initiatives
Table 64. Cipla Profiles
Table 65. Cipla Injectable Anthelmintic Drugs Product Introduction
Table 66. Cipla Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Cipla Strategic initiatives
Table 68. Sun Pharmaceutical Industries Profiles
Table 69. Sun Pharmaceutical Industries Injectable Anthelmintic Drugs Product Introduction
Table 70. Sun Pharmaceutical Industries Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Sun Pharmaceutical Industries Strategic initiatives
Table 72. Amneal Pharmaceuticals Profiles
Table 73. Amneal Pharmaceuticals Injectable Anthelmintic Drugs Product Introduction
Table 74. Amneal Pharmaceuticals Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Amneal Pharmaceuticals Strategic initiatives
Table 76. Zoetis Profiles
Table 77. Zoetis Injectable Anthelmintic Drugs Product Introduction
Table 78. Zoetis Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Zoetis Strategic initiatives
Table 80. GlaxoSmithKline Profiles
Table 81. GlaxoSmithKline Injectable Anthelmintic Drugs Product Introduction
Table 82. GlaxoSmithKline Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. GlaxoSmithKline Strategic initiatives
Table 84. Bayer Profiles
Table 85. Bayer Injectable Anthelmintic Drugs Product Introduction
Table 86. Bayer Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Bayer Strategic initiatives
Table 88. Merck Profiles
Table 89. Merck Injectable Anthelmintic Drugs Product Introduction
Table 90. Merck Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Merck Strategic initiatives
Table 92. Boehringer Ingelheim International Profiles
Table 93. Boehringer Ingelheim International Injectable Anthelmintic Drugs Product Introduction
Table 94. Boehringer Ingelheim International Injectable Anthelmintic Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Boehringer Ingelheim International Strategic initiatives
